Tag: PIK3CA

Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Read the Full Video Transcript Sam Chang: Hello everyone, I’m Sam Chang. I’m a urologist at Vanderbilt University in Nashville, Tennessee and we’re quite fortunate to have a rising superstar in urologic oncology, Dr. Tim Clinton. Tim was a resident at UT Southwestern and finished his fellowship at Memorial Sloan…

Continue Reading Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer

Burning Rock’s precision oncology diagnostics product supports advancement in late-stage … | News

GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in…

Continue Reading Burning Rock’s precision oncology diagnostics product supports advancement in late-stage … | News

PFS Improvement Seen With Capivasertib/Fulvestrant in HR+/HER2- Breast Cancer

Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the methods, design, and key findings from the phase 3 CAPItello-291…

Continue Reading PFS Improvement Seen With Capivasertib/Fulvestrant in HR+/HER2- Breast Cancer

Burning Rock Biotech highlights breast cancer study using its genomic profiling test

Precision oncology firm Burning Rock Biotech on Thursday announced that its genomic profiling test, OncoScreen Plus, was used in a phase III multiregional breast cancer clinical trial, alongside Foundation Medicine’s FoundationOneCDx. In the study, OncoScreen Plus was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in…

Continue Reading Burning Rock Biotech highlights breast cancer study using its genomic profiling test

Updates in soft tissue sarcoma

Sarcoma describes a broad group of cancers that originate in the bones and soft or connective tissues, forming in the blood vessels, nerves, muscle, fat, tendons and the lining of the joints. With over 70 types of sarcomas, treatment for this unique cancer depends on the sarcoma type, its location…

Continue Reading Updates in soft tissue sarcoma

IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Differential expression analysis We downloaded GSE125361 (n = 48) microarray data from the Gene Expression Omnibus (GEO) database, which included 45 myeloma samples and 3 controls, for expression analysis of IL5RA in cancer16. Additionally, we analyzed the expression of IL5RA in smoldering myeloma (SMM) patients who progressed to active MM (n = 10) and…

Continue Reading IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Molecular profiling reveals common changes in matched pairs of HNSCC primary tumor and metastasis-derived cell lines Identification of both genetic and functional differences between primary and metastatic variants of HNSCC would be enabled by in vitro models derived independently from these sites from the same patient. Unfortunately, HNSCC tumor cells…

Continue Reading Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

New Trials in Breast Cancer: Could Your Patient Benefit?

Several new clinical trials in breast cancer have opened in recent months. Maybe one of your patients could benefit from enrolling. Locally advanced unresectable or metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer. Adults with this type of breast cancer whose disease has progressed despite treatment with a cyclin-dependent kinase 4/6 inhibitor…

Continue Reading New Trials in Breast Cancer: Could Your Patient Benefit?

Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

Karakas, B., Bachman, K. E., & Park, B. H. (2006). British Journal of Cancer, 94, 455–459. Article  CAS  PubMed  PubMed Central  Google Scholar  Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., et al. (2004). British Journal of Cancer, 91, 355–358. Article  CAS  PubMed  PubMed Central  Google…

Continue Reading Novel Method for Detection of PIK3CA Mutations in Circulating Tumor DNA of Patients with Colorectal Cancer

Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

Claudine Isaacs, MD (Moderator) Medical Director Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research Professor of Medicine and Oncology Associate Director of Clinical Research and Leader, Clinical Breast Cancer Program Lombardi Comprehensive Cancer Center at Georgetown University Washington, DC DISCUSSION QUESTIONS What are your reactions to…

Continue Reading Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

Multi-omics analyses of the ICC samples Following multiregional sampling of primary ICC cases, we performed multi-omics analyses, including genome, transcriptome, proteome, and metabolome analysis. We used 10 (67 samples), 11 (88 samples), 10 (49 samples) and 10 (49 samples) ICC cases for WES, whole-transcriptome sequencing, proteomic analysis, and metabolomic analysis,…

Continue Reading Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma

ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

Genomic profiling of circulating tumor DNA (ctDNA) with a large panel appeared feasible in a routine setting and helped to obtain relevant molecular information that could inform strategies with targeted therapies for patients with metastatic solid tumors, according to findings from the prospective PRISM study published in Annals of Oncology….

Continue Reading ctDNA Genomic Profiling Can Guide Targeted Therapy in Advanced Cancer

IJMS | Free Full-Text | Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression

1. Introduction Lung cancer is the second most frequent cancer and the leading cause of cancer death in 2020, representing approximately 1 in 10 (11.4%) cancers diagnosed and 1 in 5 (18.0%) deaths [1]. In Lithuania, with a population of 2.7 million, a rough number of 1500 new cases of…

Continue Reading IJMS | Free Full-Text | Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression

Cancer Tumor Profiling Global Market Report 2023

ReportLinker Major players in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc. New York, March 03, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Tumor Profiling Global…

Continue Reading Cancer Tumor Profiling Global Market Report 2023

Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously

We aimed to assess the extent to which it was possible to effectively normalize and combine microarray and RNA-seq data with existing methods for use as a training set for machine learning applications. We assessed performance on holdout sets composed entirely of microarray data and entirely of RNA-seq data. To…

Continue Reading Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously

Relay Therapeutics: It Could Be Time To ‘Be Greedy When Others Are Fearful’ (NASDAQ:RLAY)

domoyega/E+ via Getty Images Investment Overview – Cash Intensive But Cash Rich – At Current Price Relay Offers The Patient Investor Value I have covered Relay Therapeutics (NASDAQ:RLAY) several times for Seeking Alpha since the company completed what was, at the time, the third largest biotech IPO in history, raising…

Continue Reading Relay Therapeutics: It Could Be Time To ‘Be Greedy When Others Are Fearful’ (NASDAQ:RLAY)

IJMS | Free Full-Text | Endothelial Differentiation of CCM1 Knockout iPSCs Triggers the Establishment of a Specific Gene Expression Signature

1. Introduction Cerebral cavernous malformations (CCMs) are capillary–venous lesions which are primarily found in the brain and spinal cord [1]. The familial form of this neurovascular disorder is inherited in an autosomal dominant manner with incomplete penetrance. Pathogenic variants in the CCM1 gene (also known as KRIT1) can be identified…

Continue Reading IJMS | Free Full-Text | Endothelial Differentiation of CCM1 Knockout iPSCs Triggers the Establishment of a Specific Gene Expression Signature

Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer

Clinicopathological characteristics The clinicopathological features of the 56 stage IV GC patients are shown in Table 1. There were 29 males and 27 females. The mean age was 65.8 years old. The tumor was located mostly in the middle third of the stomach. Approximately 69.6% of the 56 patients had…

Continue Reading Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer

Table of Pharmacogenomic Biomarkers in Drug Labeling

  Abacavir Infectious Diseases HLA-B Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions   Abemaciclib (1) Oncology ESR(Hormone Receptor) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (2) Oncology ERBB2(HER2) Indications and Usage, Adverse Reactions, Clinical Studies   Abemaciclib (3) Oncology MKI67 Indications and Usage, Dosage and Administration,…

Continue Reading Table of Pharmacogenomic Biomarkers in Drug Labeling

Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight

2023 is well underway now, and the key story is the sudden change in sentiment on the financial front. Last year’s bearish trend and headwinds are well known. Stubborn inflation, the Fed’s rapid increase in interest rates, the risk of recession, China’s shutdowns, and Russia’s Ukraine invasion; they all weighed…

Continue Reading Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight

CfDNA Alterations in 1671 Patients with Advanced BTC: A Clinical Landscape

The following is the summary of  “Clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer” published in the December 2022 issue of Oncology by Berchuck, et al. Targeted medicines have revolutionized clinical care of advanced biliary tract cancer (BTC). In contrast to conventional tissue analysis,…

Continue Reading CfDNA Alterations in 1671 Patients with Advanced BTC: A Clinical Landscape

APOBEC mutagenesis is a common process in normal human small intestine

The landscape of somatic mutation in normal human small intestinal crypts The base of each small intestinal crypt is occupied by stem cells, and the descendants of a single recent ancestor stem cell comprise most cells in each crypt19,20. Therefore, isolation of single crypts provides relatively homogeneous clones of cells…

Continue Reading APOBEC mutagenesis is a common process in normal human small intestine

Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

Cell-type annotation scRNA-seq data were filtered to discard low-quality cells and doublets (Supplementary Fig. 1, Extended Data Fig. 1 and Methods). Supervised clustering (Reference Component Analysis v2 (RCA2)) at low resolution grouped cells into 11 major cell types (Extended Data Fig. 1). To identify epithelial cell subtypes, we initially analyzed…

Continue Reading Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

A hypoxia-related signature in lung squamous cell carcinoma

Introduction Lung cancer is the major leading cause of tumour-related deaths throughout the world, while lung squamous cell carcinoma (LUSC) as the second most common histological type of lung cancer.1 Each year, almost 1.8 million people are diagnosed with lung cancer worldwide and 400,000 of these die from LUSC.2,3 Due to…

Continue Reading A hypoxia-related signature in lung squamous cell carcinoma

RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Significance Hairpin pyrrole-imidazole (Py-Im) polyamides can be programmed to bind a broad repertoire of DNA sequences. Py-Im small molecules can be used to target cancer-specific coding regions and block transcription elongation. This transcription blockage by Py-Im cannot be rescued by transcription elongation factors, such as TFIIS. The mechanism by which…

Continue Reading RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 andinitiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and breast cancer CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision…

Continue Reading Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Genomic testing varies in the academic and community setting. For community settings, commercial panels are available. However, academic settings have access to tools that provide a more comprehensive views of the genome. Investigators used patient-derived UC organoid (PDO) harboring FGFR3, PIK3CA, and CDKN2A mutations. Dose-response curves of alpelisib (Piqray), abemaciclib…

Continue Reading Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Continue Reading Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer

This article was originally published here Clin Genitourin Cancer. 2021 Jul 31:S1558-7673(21)00151-8. doi: 10.1016/j.clgc.2021.07.012. Online ahead of print. ABSTRACT BACKGROUND: There has been considerable interest in ctDNA next generation sequencing platforms to assess genomic alterations in mCRPC given its accessibility and identification of temporal genomic data. PATIENTSAND METHODS: In this…

Continue Reading Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer